The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants < 29 weeks’ gestation

BACKGROUND: Bronchopulmonary dysplasia (BPD) is a major cause of mortality and long-term respiratory and neurological morbidity in very preterm infants. While survival rates of very preterm infants have increased over the past two decades there has been no decrease in the rate of BPD in surviving in...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:BMC Pediatr
Hoofdauteurs: Collins, Carmel T., Gibson, Robert A., Makrides, Maria, McPhee, Andrew J., Sullivan, Thomas R., Davis, Peter G., Thio, Marta, Simmer, Karen, Rajadurai, Victor S.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2016
Onderwerpen:
Study Protocol
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896378/
https://ncbi.nlm.nih.gov/pubmed/27250120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12887-016-0611-0
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items